The Wall Street Journal Science reporters sit at an unusual intersection: rigorous evidence, market consequence, and reader utility. They don't cover "science" as a curiosity beat — they cover it as a force that moves companies, policy, and portfolios.

This guide distills how to earn their attention with less wasted outreach. It assumes you've already done the homework; now you need the calibration.

WSJ science coverage skews toward consequence. Think biotech trial data with commercial ripple, AI research with labor implications, climate science with regulatory teeth, and public-health findings that change behavior.

Pure discovery stories rarely clear the bar on their own. A finding needs a stake: a company, a market, a lawsuit, a budget line, or a clearly affected population.

Methodology matters more here than at general-interest outlets. Reporters will ask who funded the study, how the sample was built, and whether the result replicates.

The WSJ science bench is deep — 24+ active bylines — and notably porous. Health, biotech, tech, and investigations reporters routinely cross into science stories.

Directory entries such as Tali Arbel, Lizeth Beltran, Angus Berwick, and Katie Bindley illustrate the spread. Verify each writer's recent output before pitching; beat lines shift quarterly.

Treat any "The Wall Street Journal Science reporters list" as a starting map, not a final answer. Cross-check bylines from the last 60 days on your specific subtopic.

WSJ Science journalists respond to numbers with denominators. "One in five" beats "many." Absolute figures beat relative risk alone.

Strong angles cluster around four frames: money, regulation, risk to a defined population, and competitive disruption. Pick one and build the pitch around it.

Exclusivity is currency. A first look at a dataset, an internal memo, or an unpublished chart will outperform a press release every time.

• Commercial impact: trial results that reset a sector's expectations
• Policy friction: science that collides with FDA, EPA, or state law
• Replication and retraction: integrity stories travel fast
• Consumer-facing risk: what a reader should actually do differently

Avoid: incremental rodent studies, "first-ever" claims without context, and anything requiring three paragraphs of setup before the payoff.

Verify your "The Wall Street Journal Science journalists contacts" before sending. WSJ addresses follow predictable patterns, but guessing wrong burns credibility fast.

Prefer a direct, individual email over a newsroom alias. Reference a specific recent piece and explain — in one sentence — why your story extends it.

Never attach unsolicited files on first contact. Put the substance in the body and offer the deck, dataset, or paper on request.

Follow-up cadence: one nudge at 48 hours, one at seven days, then stop. Silence is an answer.

• Subject line: concrete and numeric, under 10 words
• First line: the news, stated plainly
• Second line: the stake — who is affected and how much
• Third line: why this reporter, referencing their prior coverage
• Close: what you can provide exclusively and your embargo window

Run this before you hit send. If any box fails, rewrite rather than send.

• Recent byline check on the specific writer within 90 days
• One-sentence news hook, no jargon
• A hard number with a clear denominator
• A named, independent expert available for comment
• An exclusivity offer — data, document, or first interview
• Embargo terms stated explicitly
• Under 150 words, no attachments
• Verified contact, spelled correctly

The through-line: treat The Wall Street Journal Science reporters as business reporters who happen to cover evidence. Give them the stake, the number, and the exclusive — and the science will follow.